Western blotting evaluated the p-EGFR/KRAS/p-ERK1/2 signaling pathway in pancreatic cancer cells (PANC-1 and MIA PACA-2) under individual and combined CSI and erlotinib treatments (Figure 7C). This evidence concerns the gene EGFR and familial pancreatic carcinoma.